Daniel Lee
Impact in
-
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 10%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Treatments and Mutations 18
- Brain Metastases and Treatment 3
- Renal cell carcinoma treatment 3
- Oncology 8
- Cancer Immunotherapy and Biomarkers 4
- Lung Cancer Research Studies 3
- Co-authors
- Joong Sun Lee (2 shared papers)Chong Hyun Suh (2 shared papers)Sang Jun Park (2 shared papers)H. T. Kim (1 shared paper)Hanjong Ahn (1 shared paper)Hun-Mo Ryoo (1 shared paper)Jun Hyuk Hong (2 shared papers)Myung‐Ju Ahn (5 shared papers)
- Journals
- Annals of Oncology (18 papers)Journal of Thoracic Oncology (5 papers)Lung Cancer (2 papers)Clinical Cancer Research (1 paper)Therapeutic Innovation & Regulatory Science (1 paper)
- Partner nations
- South KoreaUnited StatesSpain
In The Last Decade
Daniel Lee
36 papers receiving 1.1k citations
Daniel Lee's Hit Papers
Peers
Comparison fields: 5 of 50
- Pulmonary and Respiratory Medicine 748
- Oncology 186
- Cancer Research 46
- Hematology 41
- Otorhinolaryngology 16
Countries citing papers authored by Daniel Lee
This map shows the geographic impact of Daniel Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lee more than expected).
Fields of papers citing papers by Daniel Lee
This network shows the impact of papers produced by Daniel Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lee. The network helps show where Daniel Lee may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 278 | |
| 2 | Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial Hit paper breakdown → | 2022 | 137 |
| 3 | 2015 | 91 | |
| 4 | 2022 | 91 | |
| 5 | 2013 | 83 | |
| 6 | 2020 | 71 | |
| 7 | 2023 | 52 | |
| 8 | 2017 | 40 | |
| 9 | 2020 | 39 | |
| 10 | 2010 | 34 | |
| 11 | 2013 | 25 | |
| 12 | 2009 | 16 | |
| 13 | 2020 | 16 | |
| 14 | 2024 | 15 | |
| 15 | 2019 | 13 | |
| 16 | 2023 | 12 | |
| 17 | 2014 | 11 | |
| 18 | 2021 | 7 | |
| 19 | 2017 | 6 | |
| 20 | 2017 | 6 |
About Daniel Lee
Daniel Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Cancer Research and Genetics, having authored 36 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (4 papers), Brain Metastases and Treatment (3 papers), Lung Cancer Research Studies (3 papers), Renal cell carcinoma treatment (3 papers), Hemostasis and retained surgical items (1 paper), Abdominal vascular conditions and treatments (1 paper) and MicroRNA in disease regulation (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (748 citations), Oncology (186 citations), Cancer Research (46 citations), Hematology (41 citations) and Otorhinolaryngology (16 citations). Daniel Lee has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Joong Sun Lee, Chong Hyun Suh, Sang Jun Park, H. T. Kim, Hanjong Ahn, Hun-Mo Ryoo, Jun Hyuk Hong, Myung‐Ju Ahn, Cheryn Song and Bumsik Hong. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Cancer Research and Therapeutic Innovation & Regulatory Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.